Cannabis rescheduling has moved from speculation to partial reality, and the tax stakes for operators are enormous. In April 2026, the Justice Department placed certain marijuana products in Schedule III of the Controlled Substances Act while opening a hearing on whether all marijuana should follow. For cannabis businesses, the central question is what a full move to Schedule III would mean for Internal Revenue Code Section 280E, the provision that has driven effective federal tax rates far above what ordinary businesses pay. This article frames the current status carefully and lays out what operators should model now, before any broader change is final.
Quick answer: As of mid-2026, only marijuana in FDA-approved drug products and marijuana under qualifying state medical licenses has been moved to Schedule III. Everything else, including adult-use and bulk marijuana, remains in Schedule I. Section 280E applies only to Schedule I and II substances, so a full Schedule III reclassification would remove 280E from cannabis operators entirely. Until the broader rescheduling hearing concludes and a final order issues, 280E still governs most of the industry, and businesses should plan for both outcomes rather than assume relief has arrived.
Where Cannabis Rescheduling Actually Stands
On April 23, 2026, the Acting Attorney General signed a final order transferring two specific categories of marijuana from Schedule I to Schedule III, effective April 28, 2026. Those categories are marijuana contained in a Food and Drug Administration approved drug product and marijuana subject to a qualifying state-issued medical marijuana license. According to the Justice Department, the change reaches medical marijuana regulated under state licenses, and roughly 40 states currently operate medical marijuana programs. The official summary is available in the Justice Department announcement.
Everything outside those two buckets stays in Schedule I. That includes adult-use (recreational) marijuana, unlicensed crops, bulk marijuana, and extracts or derivatives that are not part of an FDA-approved product. The practical effect is a split market: a portion of the industry has shifted out of Schedule I, while a large share remains exactly where it was.
The broader question, whether all marijuana should move to Schedule III, is not settled. The DEA scheduled an expedited administrative hearing beginning June 29, 2026, with a directive to conclude no later than July 15, 2026. A hearing is not a final rule. The agency must still weigh the record and issue a decision, and any resulting order could be challenged. Operators should treat full rescheduling as pending and contingent, not as accomplished policy.
This sequence traces back to Executive Order 14370, issued December 18, 2025, which directed the Attorney General to complete the rescheduling rulemaking as expeditiously as possible. Background and primary documents are available through the DEA’s marijuana rescheduling regulatory actions page. Because the legal landscape continues to shift, owners should confirm their specific status with counsel rather than rely on headlines.
The distinction between a notice of proposed rulemaking, a hearing, and a final order matters for planning. Each step has its own timeline and its own opportunity for public comment or legal challenge. A business that mistakes a procedural milestone for a settled outcome can make costly decisions based on a result that has not yet occurred. Tracking the actual docket, rather than secondary commentary, keeps expectations anchored to what has legally taken effect.
How 280E Works and Why Schedule III Changes Everything
Section 280E denies deductions and credits for any business that traffics in controlled substances listed in Schedule I or II of the Controlled Substances Act. Congress enacted it in 1982 in response to a Tax Court decision that had allowed a drug trafficker to claim business deductions, and the language reaches state-legal cannabis operators because marijuana has, until recently, sat in Schedule I. The reference to Schedule I and II is the hinge: 280E does not apply to substances in Schedule III, IV, or V.
The result for cannabis companies has been punishing. A dispensary cannot deduct ordinary and necessary business expenses under Section 162, state and local taxes under Section 164, depreciation under Section 167, or most other line items that conventional retailers take for granted. Rent, marketing, employee wages outside of production, and banking fees generally cannot reduce federal taxable income. The IRS guide to business expense resources helps frame what a normal business deducts, almost none of which a 280E-bound operator can claim.
The one path that survives is cost of goods sold. Courts and the IRS allow cannabis businesses to reduce gross receipts by COGS, because COGS is treated as a reduction in arriving at gross income rather than as a deduction. For a cultivator, COGS can capture a meaningful share of costs, including direct labor and growing inputs. For a pure retailer, COGS is largely limited to the invoice cost of inventory, which leaves most operating expenses non-deductible and federal tax bills disproportionately high.
This is why two cannabis companies with identical revenue and identical real-world profit can owe vastly different federal tax. The cultivator absorbs more of its costs into inventory and recovers them through COGS, while the retailer watches rent and payroll fall outside the only deductible channel available. The disparity has shaped how operators structure entities, allocate functions, and price their products for years.
If marijuana moves entirely to Schedule III, 280E stops applying to cannabis businesses. They would deduct ordinary and necessary expenses like any other company, and the COGS workarounds that have shaped cannabis accounting for years would lose their outsized importance. That is the prize the industry has watched for, and it is why the distinction between the partial 2026 reclassification and a full rescheduling matters so much for tax planning.
What the Partial Reclassification Means Today
For operators whose product falls within the rescheduled categories, FDA-approved marijuana drug products and state-licensed medical marijuana, the analysis has already shifted. Because those products are now in Schedule III, the trade or business associated with them is no longer trafficking in a Schedule I or II substance, which removes the 280E bar for that activity. Affected medical operators may be positioned to deduct ordinary and necessary expenses going forward, though the timing of that relief depends on how their products and licenses map to the rescheduled categories.
The reclassification has also raised the question of whether any relief from Section 280E could reach prior years in which operators held qualifying state licenses, an issue the IRS would need to address through guidance. Nothing here is automatic. The timing of when an operator’s product moved to Schedule III, how the business is structured, and how books are kept all affect whether and when relief is available. This is exactly the kind of fact-specific determination that warrants professional review.
For the larger adult-use market and any operator outside the rescheduled categories, nothing has changed yet. Those businesses remain Schedule I, 280E continues to apply in full, and aggressive deduction positions taken in anticipation of a favorable hearing outcome carry real audit and penalty exposure. Position your filings on the law as it stands today, and document the basis for any COGS allocation carefully. Firms that serve the cannabis industry can help separate what is settled from what is still speculative.
Businesses that span both worlds, for example a vertically integrated company with a medical license and an adult-use line, face the hardest sorting problem. The same legal entity may now have one activity outside 280E and another still inside it. Clean allocation of expenses, revenue, and inventory between those activities becomes essential, because a sloppy line between them invites both lost deductions and audit risk.
What to Model Now: Planning for Both Outcomes
The prudent approach is scenario planning. Build a baseline that assumes 280E continues to apply, so cash flow and estimated tax payments reflect the higher effective rate the industry knows well. Then build a parallel model assuming a full Schedule III move, with ordinary and necessary expenses fully deductible, to understand the upside and to be ready to adjust quickly if a final order issues.
Recordkeeping is the connective tissue between both scenarios. Maintain a clean separation between COGS and operating expenses, support inventory costing with contemporaneous documentation, and track which products and licenses fall inside the rescheduled categories versus outside them. If any retrospective 280E relief becomes available, the operators who can substantiate prior-year expenses and license status will be best positioned to claim it. Disorganized books will forfeit relief that better-documented competitors capture.
Watch the procedural calendar closely. The hearing window of June 29 through mid-July 2026 will not, by itself, change anyone’s tax obligations; a final order and any IRS guidance will. Avoid restructuring entities or accelerating deductions on the assumption that full rescheduling is a certainty. Coordinated guidance from advisors who understand both the tax code and the regulatory timeline reduces the risk of acting too early. Pease Bell’s tax advisory services can help operators stress-test these scenarios and align estimated payments with the most likely outcome.
Cash management deserves equal attention. If relief arrives, an operator that overpaid under 280E may be entitled to a refund or a reduced future liability, but only after the order takes effect and the mechanics are clear. Setting aside reserves as though 280E still applies protects against a hearing outcome that disappoints, while a documented upside model lets the business move fast if the outcome is favorable.
Finally, factor state conformity into the model. Some states decouple from 280E and already allow deductions for state income tax purposes, while others conform to federal treatment. A federal change to Schedule III would not uniformly resolve state-level exposure, so the full picture requires looking at each jurisdiction in which the business operates.
Frequently Asked Questions
Has cannabis been rescheduled to Schedule III?
Only in part. As of mid-2026, marijuana in FDA-approved drug products and marijuana under qualifying state medical licenses moved to Schedule III effective April 28, 2026. Adult-use marijuana, bulk marijuana, and unlicensed product remain in Schedule I, and a hearing on broader rescheduling is pending rather than decided.
Does Section 280E still apply to my cannabis business?
It depends on where your product sits. If your business involves marijuana that remains in Schedule I, 280E still applies and limits you to cost of goods sold. If your product falls within the rescheduled Schedule III categories, the 280E bar should no longer apply to that activity, but you should confirm the specifics with a tax professional.
If marijuana moves fully to Schedule III, when would 280E stop applying?
Section 280E stops applying to a substance once it is no longer in Schedule I or II. A full reclassification would remove the 280E bar for cannabis businesses, but only after a final order takes effect. The exact tax year of relief would depend on the order’s effective date and any IRS guidance, so timing should not be assumed in advance.
What should I do before any broader rescheduling is finalized?
Keep filing under current law, maintain rigorous separation of COGS and operating expenses, and document license status and product categories. Build both a 280E and a non-280E financial model so you can adjust quickly. Work with advisors who track the regulatory timeline so you do not act prematurely on an outcome that is not yet final.
